

Key Statistics (USD)

Price	178.45
Market Cap	315.972B
Enterprise Value	362.54B
PEG Ratio (5 yr. expected)	0.49
52 weeks high	182.89
52 weeks low	130.96
Beta (5Y-monthly)	0.56
Dividend yield %	3.52%
EPS (TTM)	2.71
1-Yr Stock performance	14.91%

Growth Rates

	Company	3-Yr Avg
Revenues	-5.42%	7.57%
Earnings	-66.97%	1,687.15%
Free Cash Flow	-8.76%	8.94%

Margins

	Company	3-Yr Avg.
Gross Profit Margin	60.28%	69.05%
Operating Margin	22.34%	28.86%
Net Profit Margin	8.51%	20.73%

Key Ratios

	Company	3-Yr Avg
Current Ratio	0.87x	-
Total Ratio	1.08x	-
Financial Leverage	13.00x	10.30x
ROE	78.98%	78.38%
ROA	2.69%	3.31%
ROIC	-	-

Valuation Metrics

	Company	3-Yr Avg
Price to Sales	5.07x	4.44x
Price to Earnings	56.99x	30.47x
Price to Free Cash Flow	4.95x	4.62x
Price to Book Value	26.57x	17.99x

Firm's Brief Description.

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq oncology products, which includes aesthetics products that such as Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities and more. The Company offers a PINK1 activator which is designed to address mitochondrial dysfunction. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector Overview

- Mirador debuts with \$400M, picking up where immune drugmaker Prometheus left off
- Bayer streamlines pharma leadership team amid company shakeup
- NextCure to lay off 37% of staff, dial back research plans

Fundamental Analysis

Compared to the previous year, AbbVie's stock price has surged by approximately 14.91%, reaching \$178.45, with a market capitalization of \$315.972 billion and a total enterprise value of \$362.54 billion. With a beta of 0.56, indicating lower volatility compared to the market average, AbbVie appears to offer a relatively safer investment option for risk-averse investors. Despite a -5.42% decrease in revenue, which is below the 3-year average of 7.57%, AbbVie's earnings have plummeted to -66.97%, signaling a concerning downturn in financial performance. Furthermore, the company has experienced a slight decline in profitability, with lower Gross Profit Margin (60.28% vs. 3-year average of 69.05%), Operating Margin (22.34% vs. 3-year average of 28.86%), and Net Profit Margin (8.51% vs. 3-year average of 20.73%), possibly indicating challenges in sustaining previous levels of operational efficiency. With a financial leverage of 13.00x and an impressive ROE of 78.98%, AbbVie exhibits a significant risk appetite, suggesting a willingness to take on substantial debt levels to maximize returns. Additionally, positive indicators such as P/S, P/E, P/B and P/FCF ratios bode well for investors. Overall, these factors warrant careful consideration for investors evaluating AbbVie's investment potential.

Target Price (1 year forward): 183.47\$

DISCLAIMER

THE FINANCE CLUB OF UNIVERSITY OF MACEDONIA, THESSALONIKI, GREECE

The Finance Club of University of Macedonia - www.financeclub.gr is an independent non-profitable student organization founded by students of the University of Macedonia, Greece (UoM - www.uom.gr) that aims to build strong relations between the market and the University. Though based in the University of Macedonia, it also operates via associates in Aristotle University of Thessaloniki, Greece and other institutions. The Club's goal is to give its members the chance to view the market in a more practical approach rather than solely relying on the abstract knowledge offered by the university. In order to achieve this goal, the Club organizes various events like conferences, workshops and seminars. Moreover, its members are able to cooperate with companies by taking up real case projects to work on along with the managers of the associated companies. In addition, the Club is trying to build and expand its network among students, market professionals and professors therefore giving its members a very broad pool of potential partners and employers.

This report has been compiled by the authors mentioned above and published by them via the Finance Club UoM site and many other platforms. The club confirms that the authors are active members at the time this article is published but emphasizes the fact that opinions and views given by the authors in this article are their own views. Finance Club UoM takes no responsibility for the completeness or correctness of information provided. No investment advice is given with the text above and the reader should not take any financial position based on the information published in this article. The Club recommends extensive research by the reader before investing in any financial asset. General this report may be based on the information extracted from various sources including but not limited to various companies' and statistical agencies' websites, online portals, third-party research, annual reports etc. No representation or warranty of any kind is or may be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, any projections or futuristic statement contained herein or any underlying assumptions. This article may include descriptions, statements, estimates and projections/futuristic statements with respect to current and anticipated performance of the underlying. Such statements, estimates and projections reflect various assumptions and best estimates made by the participants concerning anticipated results, whose assumptions and estimates may or may not prove to be accurate or correct. There are no assurances whatsoever that any statements, estimates or projections contained in this article, including without limitation any financial or business projections, accurately present in all material respects the underlying's financial and/or business position as of the respective dates specified and the results of its operations for any respective periods indicated. No copyright or trademark infringement is intended in any form.

© **Copyright 2020. Finance Club UoM**